Sareum Partner Sierra Oncology To Present Positive SRA737 Results

15th Mar 2018 13:55

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual meeting of the American Association of Cancer Research.

The results show SRA737 has anti-tumour activity as a monotherapy in both CCNE1-driven cancer models and in cancer models resistant to poly ADP-ribose inhibitor therapy, which Sareum said warrants further investigation in human clinical studies.

The meeting will be held in Chicago in mid-April.

Shares were up 1.7% on Thursday at 0.839 pence each.

---

Related Shares:

Sareum